{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:42:47Z","timestamp":1791142967714,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,1,29]],"date-time":"2009-01-29T00:00:00Z","timestamp":1233187200000},"content-version":"vor","delay-in-days":3408,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[1999,10]]},"abstract":"<jats:p>\n<jats:list list-type=\"explicit-label\">\n<jats:list-item><jats:p>The effects of injections i.c.v. of quipazine, (2\u2003\u03bcmol\u2003kg<jats:sup>\u22121<\/jats:sup>) and 1\u2010(2,5\u2010di\u2010methoxy\u20104\u2010iodophenyl)\u20102\u2010aminopropane (DOI; 2\u2003\u03bcmol\u2003kg<jats:sup>\u22121<\/jats:sup>) on renal sympathetic and phrenic nerve activity, mean arterial blood pressure (MAP) and heart rate were investigated in \u03b1\u2010chloralose anaesthetized rats pretreated with a peripherally acting 5\u2010HT<jats:sub>2<\/jats:sub> receptor antagonist.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Quipazine or DOI caused a rise in MAP which was associated with a tachycardia and renal sympathoinhibition in rats pretreated (i.c.v.) with the antagonist vehicle 10% PEG. These effects of quipazine were completely blocked by pretreatment with cinanserin (a 5\u2010HT<jats:sub>2<\/jats:sub> receptor antagonist) and attenuated by spiperone (a 5\u2010HT<jats:sub>2A<\/jats:sub> receptor antagonist). However, pretreatment with SB200646A (a 5\u2010HT<jats:sub>2B\/2C<\/jats:sub> receptor antagonist) only blocked the sympathoinhibition, while pretreatment with SB204741 (a 5\u2010HT<jats:sub>2B<\/jats:sub> receptor antagonist) reversed the sympathoinhibition to excitation as it also did for DOI. Quipazine also caused renal sympathoexcitation in the presence (i.v.) of a vasopressin V<jats:sub>1<\/jats:sub> receptor antagonist.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Injection (i.v.) of the V<jats:sub>1<\/jats:sub> receptor antagonist at the peak pressor response evoked by quipazine alone and in the presence of SB204741 caused an immediate fall in MAP. For quipazine alone the renal sympathoinhibition was slowly reversed to an excitation, while the renal sympathoexcitation observed in the presence of SB204741 was potentiated. In both, the quipazine\u2010evoked tachycardia was unaffected.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The data indicate that cardiovascular responses caused by i.c.v. quipazine and DOI are primarily due to activation of central 5\u2010HT<jats:sub>2A<\/jats:sub> receptors, which causes the release of vasopressin and a tachycardia. This released vasopressin appears to suppress a 5\u2010HT<jats:sub>2A<\/jats:sub> receptor\u2010evoked central increase in sympathetic outflow, which involves the activation of central 5\u2010HT<jats:sub>2B<\/jats:sub> receptors indirectly by the released vasopressin.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p><jats:p> <jats:italic>British Journal of Pharmacology<\/jats:italic> (1999) <jats:bold>128<\/jats:bold>, 530\u2013542; doi:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/sj.bjp.0702822\">10.1038\/sj.bjp.0702822<\/jats:ext-link><\/jats:p>","DOI":"10.1038\/sj.bjp.0702822","type":"journal-article","created":{"date-parts":[[2005,1,28]],"date-time":"2005-01-28T20:12:18Z","timestamp":1106943138000},"page":"530-542","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Evidence for a role for central 5\u2010HT<sub>2B<\/sub> as well as 5\u2010HT<sub>2A<\/sub> receptors in cardiovascular regulation in anaesthetized rats"],"prefix":"10.1111","volume":"128","author":[{"given":"Ian D","family":"Knowles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G","family":"Ramage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,1,29]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"829","article-title":"Activation of serotonin2 (5\u2010HT2) receptors by quipazine increases arterial pressure and renin secretion in conscious rats","volume":"243","author":"ALPER R.H.","year":"1987","journal-title":"J. Pharmacol. & Exp. Ther."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1992.tb13401.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb16658.x"},{"key":"e_1_2_7_5_1","first-page":"1","volume-title":"Central Mechanisms Involved in Cardiovascular Regulation","author":"BERECEK K.H.","year":"1993"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb14977.x"},{"key":"e_1_2_7_7_1","first-page":"1839","volume-title":"The Lung: Scientific Foundations","author":"COLERIDGE H.M.","year":"1997"},{"key":"e_1_2_7_8_1","first-page":"1027","article-title":"Central and peripheral injections of the 5\u2010HT2 agonist, 1\u2010(2,5\u2010dimethoxy\u20104\u2010iodophenyl)\u20102\u2010aminopropane, modify cardiovascular function through different mechanisms","volume":"259","author":"DEDEO\u011eLU A.","year":"1991","journal-title":"J. Pharmacol. & Exp. Therap."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0074-7696(08)61479-5"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1991.tb12172.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(96)00480-0"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00006a001"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(86)90084-1"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.54.4.355"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(69)90185-X"},{"key":"e_1_2_7_16_1","first-page":"31","volume-title":"5\u2010HT1A Agonists, 5\u2010HT3 Antagonists and Benzodiazepines: Their Comparative Behavioural Pharmacology","author":"HOYER D.","year":"1991"},{"key":"e_1_2_7_17_1","first-page":"35","volume-title":"Receptor Data for Biological Experiments: A Guide to Drug Selectivity","author":"HOYER D.","year":"1991"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(85)90123-X"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1996.tb15304.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1994.tb14808.x"},{"key":"e_1_2_7_21_1","first-page":"71P","article-title":"Evidence that central 5\u2010HT2B and 5\u2010HT2A receptors play a role in cardiovascular regulation in the anaesthetized rat","volume":"501","author":"KNOWLES I.D.","year":"1997","journal-title":"J. Physiol."},{"key":"e_1_2_7_22_1","first-page":"96P","article-title":"The pressor response evoked by activation of forebrain 5\u2010HT2A receptors involves the activation of central AT1 receptors in anaesthetized rats","volume":"123","author":"KNOWLES I.D.","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"e_1_2_7_23_1","first-page":"8P","article-title":"Activation of central 5\u2010HT2B receptors causes renal sympathoexcitation in anaesthetized rats","volume":"125","author":"KNOWLES I.D.","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(86)91161-3"},{"key":"e_1_2_7_25_1","first-page":"223P","article-title":"Evaluation of the peripheral and central antagonistic activities against 5\u2010hydroxytryptamine of some new agents","volume":"39","author":"MAWSON C.","year":"1970","journal-title":"Br. J. Pharmacol."},{"key":"e_1_2_7_26_1","first-page":"231","article-title":"Role of serotonin1A and serotonin2 receptors in the central regulation of the cardiovascular system","volume":"46","author":"MCCALL R.B.","year":"1994","journal-title":"Pharmacol. Rev."},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(85)90857-1"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000126404"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0700954"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1838(93)90341-Q"},{"key":"e_1_2_7_31_1","first-page":"132","article-title":"A new potent and specific serotonin inhibitor (SQ 10,643) 2\u2032\u2010(3\u2010dimethylaminopropylthio) cinnamanilide hydrochloride: antiserotonin activity on the uterus and on gastrointestinal, vascular and respiratory systems of animals","volume":"152","author":"RUBIN B.","year":"1964","journal-title":"Arch. Int. Pharmacodyn."},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1996.270.3.E513"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1991.tb12437.x"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(76)90788-5"},{"key":"e_1_2_7_35_1","volume-title":"Biometry: The Principles and Practice of Statistics in Biological Research","author":"SOKAL R.R.","year":"1969"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(81)90146-9"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)90668-V"},{"key":"e_1_2_7_38_1","first-page":"720","article-title":"Pharmacological characterization of the human 5\u2010hydroxytryptamine2B receptor: evidence for species differences","volume":"276","author":"WAINSCOTT D.B.","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199001000-00001"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0702822","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0702822","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/sj.bjp.0702822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T21:58:50Z","timestamp":1698530330000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/sj.bjp.0702822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1999,10]]}},"alternative-id":["10.1038\/sj.bjp.0702822"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjp.0702822","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,10]]},"assertion":[{"value":"2009-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}